Search Result

Results for "

Low-density lipoprotein cholesterol

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) LDLR (1) AMPK (1) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (5) Autophagy (12) Bacterial (4) Biochemical Assay Reagents (1) CETP (1) Cytochrome P450 (1) Endogenous Metabolite (1) Ferroptosis (2) FXR (1) HMG-CoA Reductase (HMGCR) (14) Isotope-Labeled Compounds (2) Mitophagy (5) Potassium Channel (7) PPAR (1) RAR/RXR (1) ROR (1) Ser/Thr Protease (5) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (14) Endocrinology (2) Inflammation/Immunology (2) Metabolic Disease (28) Neurological Disease (3)

By Targets:

Acyltransferase (1)

LDLR (1)

AMPK (1)

Apical Sodium-Dependent Bile Acid Transporter (1)

Apoptosis (5)

Autophagy (12)

Bacterial (4)

Biochemical Assay Reagents (1)

CETP (1)

Cytochrome P450 (1)

Endogenous Metabolite (1)

Ferroptosis (2)

FXR (1)

HMG-CoA Reductase (HMGCR) (14)

Isotope-Labeled Compounds (2)

Mitophagy (5)

Potassium Channel (7)

PPAR (1)

RAR/RXR (1)

ROR (1)

Ser/Thr Protease (5)

Thyroid Hormone Receptor (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (14)

Endocrinology (2)

Inflammation/Immunology (2)

Metabolic Disease (28)

Neurological Disease (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: LDLR LOX-1 Acyltransferase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113288

Campestanol	Others	Metabolic Disease
Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .

HY-109523

Cerivastatin sodium	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-115914

Lipid-lowering agent-1	Others	Others
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .

HY-153451

PCSK9-IN-15	Ser/Thr Protease	Metabolic Disease
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, K_D <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-145001

20-HC-Me-Pyrrolidine	Others	Metabolic Disease
20-HC-Me-Pyrrolidine is a potent Aster protein inhibitor with IC₅₀s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER) .

HY-17504B

Rosuvastatin Sodium Maximum Cited Publications 9 Publications Verification ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial	Cardiovascular Disease Metabolic Disease
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504

Rosuvastatin Calcium Maximum Cited Publications 9 Publications Verification Rosuvastatin hemicalcium; ZD 4522 Calcium	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504A

Rosuvastatin ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-W134326

Polydextrose	Biochemical Assay Reagents	Metabolic Disease
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .

HY-129982

SC-435	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
SC-435 is an apical sodium-dependent Bile acid (BA) transporter inhibitor. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .

HY-109567

Gemcabene PD-72953	Others	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-109567A

Gemcabene calcium PD-72953 calcium	Others	Metabolic Disease Inflammation/Immunology
Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-16274

Lapaquistat acetate TAK-475	Others	Metabolic Disease
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .

HY-128334

PCSK9 modulator-2	Ser/Thr Protease	Metabolic Disease
PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC₅₀ value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .

HY-146084

PCSK9 modulator-3	Ser/Thr Protease	Metabolic Disease
PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC₅₀ value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .

HY-146085

PCSK9 modulator-4	Ser/Thr Protease	Metabolic Disease
PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC₅₀ value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia .

HY-B0144AS1

Pitavastatin-d5 sodium NK-104-d₅ sodium	Apoptosis HMG-CoA Reductase (HMGCR) Mitophagy Autophagy	Metabolic Disease Cancer
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; cholesterol behenate	Endogenous Metabolite	Metabolic Disease
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-B0144A

Pitavastatin 4 Publications Verification NK-104	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-B0144B

Pitavastatin sodium NK-104 sodium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	Ser/Thr Protease	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

HY-B0144S

Pitavastatin-d4 hemicalcium NK-104-d₄ hemicalcium; Pitavastatin-d₄ hemicalcium	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Metabolic Disease Cancer
Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-B0144

Pitavastatin Calcium 4 Publications Verification NK-104 hemicalcium; Pitavastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-146398

AMPK activator 6	AMPK	Metabolic Disease
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .

HY-17504R

Rosuvastatin Calcium (Standard) 3 Publications Verification Rosuvastatin hemicalcium (Standard); ZD 4522 Calcium (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-163436

F44-A13	FXR Cytochrome P450 RAR/RXR PPAR ROR	Metabolic Disease
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .

HY-17504D

(3S,5R)-Rosuvastatin	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy	Cardiovascular Disease Metabolic Disease
(3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504C

(3R,5R)-Rosuvastatin	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy	Cardiovascular Disease Metabolic Disease
(3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-101529

Imanixil HOE-402(free base)	LDLR	Cardiovascular Disease
Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development .

HY-119265

LDL-IN-4	Acyltransferase	Metabolic Disease
LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC₅₀ of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity .

HY-12089

Torcetrapib CP-529414	CETP	Endocrinology
Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .

HY-17504AS

Rosuvastatin-d3 ZD 4522 d₃	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel	Cardiovascular Disease Metabolic Disease
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

Polydextrose	Biochemical Assay Reagents
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	Ser/Thr Protease	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; cholesterol behenate	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

Cat. No.	Product Name	Chemical Structure

HY-B0144AS1

Pitavastatin-d5 sodium
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-B0144S

Pitavastatin-d4 hemicalcium
Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

Pitavastatin-d4 hemicalcium

Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-17504AS

Rosuvastatin-d3
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks